Show simple item record

Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin

dc.contributor.authorPeters-Golden, Marc L.en_US
dc.contributor.authorShelly, Candaceen_US
dc.date.accessioned2006-04-07T20:49:08Z
dc.date.available2006-04-07T20:49:08Z
dc.date.issued1989-05-15en_US
dc.identifier.citationPeters-Golden, Marc, Shelly, Candace (1989/05/15)."Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin." Biochemical Pharmacology 38(10): 1589-1595. <http://hdl.handle.net/2027.42/27937>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6T4P-4751SWR-1CP/2/b4596ad4d261eb05029429c0eb16c00cen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27937
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2499339&dopt=citationen_US
dc.description.abstractWe have examined the effect of the oral gold compound auranofin (AF) on calcium ionophore A23187-induced arachidonic acid metabolism in the rat alveolar macrophage. Both reverse-phase high performance liquid Chromatographie and radioimmunoassay analyses revealed that AF dose-dependently inhibited leukotriene B4 and 5-hydroxyeicosatetraenoic acid synthesis in a parallel fashion with an 50 ~ 4.3 [mu]g/ml. At the same time, AF augmented A23187-induced arachidonate release and cyclooxy-genase metabolism. A possible mechanism for the inhibition of 5-lipoxygenase was suggested by the capacity of AF to dose-dependently deplete ATP (50 ~ 5.9 [mu]g/ml), a cofactor for 5-lipoxygenase. These data indicate that, at therapeutic concentrations, AF acts in vitro as a selective inhibitor of macrophage 5-lipoxygenase metabolism. This likely represents an important mechanism of action of AF in chronic inflammatory disorders.en_US
dc.format.extent911930 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleInhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofinen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan and Veterans Administration Medical Centers, Ann Arbor, MI, U.S.A.en_US
dc.contributor.affiliationumDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan and Veterans Administration Medical Centers, Ann Arbor, MI, U.S.A.en_US
dc.identifier.pmid2499339en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27937/1/0000363.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0006-2952(89)90306-7en_US
dc.identifier.sourceBiochemical Pharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.